An interesting case decided on April 3 in Florida confirms the
axiom that information that is not secret cannot be a trade secret.
Godwin Pumps of America, Inc. v. Ramer, Godwin sued its former
employee, Ramer, for, among other things, trade secret
misappropriation under Florida's Uniform Trade Secret Act (see
here for more on the Act). Godwin argued that there was nothing
in dispute for a jury to hear on Ramer's liability and moved
for the judge to enter summary judgment against Ramer. The judge
denied the motion on the trade secret claim because there was a
dispute over whether the information Ramer
acquired—including information on Godwin's customers,
pricing, products, and services—was actually secret.
Ramer argued that information on Godwin's products and pricing
is available on the Internet, that the state government publishes
information that can be used to identify Godwin's potential or
current customers, and information like that at issue in the case
is routinely acquired and collected by competitors from external
sources, such as customers. The court was convinced to let the case
go to trial. Similar arguments have held up in Massachusetts
courts. See, e.g., Campbell Soup Co. v. Giles, 47 F.3d
467, 469-70, 472 (1st Cir. 1995) (affirming denial of preliminary
injunction by Massachusetts district court in trade secret case
determined in part because "most of the marketing information
was no longer confidential in light of its public disclosure"
to customers and in published sales materials and syndicated data
The lesson here is that employers should think about the
confidential information a departed employee may possess before
filing a trade secret claim. Former employees frequently will argue
that information is not secret to defend against such claims, and
sometimes those arguments are hard to overcome.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Foley Hoag will present a 60-minute webinar on Wednesday, January 25, 2017 at 12:30 pm EST offering guidance to in-house counsel on best practices for pharmaceutical and biologics companies in selecting, vetting, and seeking approval for medication product names. The focus will be primarily on the U.S. market, although foreign strategies may be addressed as well.
25 Jan 2017, Seminar, Massachusetts, United States
Please join us on Wednesday, January 25 at the Westin Waltham Hotel for our quarterly New England M&A Forum, which brings the latest in market trends and recent legal developments to the New England M&A professionals' community.
Sellers love them, buyers hate them, but auctions are a mainstay of the M&A landscape. Our panel of experts, led by Foley Hoag partner Bill Kolb, will discuss legal, business and strategic considerations in structuring and participating in auctions from both the buy-side and the sell-side.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
In June 2016, the NHL announced that Las Vegas would be awarded an NHL franchise team, the first major professional sports team in the city and the first new expansion team for the NHL in over fifteen years.
On December 6, 2016, the parties to the complex and soon-to-be departed world of patent interferences orally argued their positions on motions in what has been described as the "biotech trial of the century"...
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).